Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma

An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study

This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.

Inclusion Criteria:

• Patients with a history of severe allergic asthma who completed the treatment period of CIGE250011E3 protocol, without experiencing any significant drug-related adverse events
• Male or female patients 12-75 years of age who have given written informed consent approved by the ethical committee

Exclusion Criteria:

• Patients who had not received study medication for greater than 84 days since visit 38 of study CIGE240011E3
• Pregnant females or nursing mothers
• Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs

Other protocol-defined inclusion/exclusion criteria may apply